Aktienanalyse zu Oncolytics Biotech Inc (ONCY)ONCYOncolytics Biotech Inc

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically cold tumors hot through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Oncolytics Biotech Inc is not a good buy right now due to its current price of $0.40, which is significantly below its 52-week high of $1.30, indicating a substantial decline in value. Additionally, the company's RSI is at a very low 12.234, suggesting it is oversold and may continue to face downward pressure. The forward P/E ratio of 45.45 indicates high expectations for future earnings that may not materialize given the company's ongoing losses, with net income consistently negative, such as -12,679,060.40 USD in Q1 2026. The main risk is the company's cash position, which is only $5.49 million, insufficient to sustain operations for the next 12 months, raising doubts about its viability.